Zhengye Biotechnology Holding Limited (ZYBT) Stock Price & Analysis
Zhengye Biotechnology Holding Limited (ZYBT) — MoonshotScore 46/100 (Fair band), calculated Oct 4, 2026. Price $1.24 (-1.59%), as of the Oct 2, 2026 trading session; market cap $58.8M.
Educational signal · not a buy or sell recommendation · How to read this
Zhengye Biotechnology Holding Limited · ZYBT · NASDAQ
Zhengye Biotechnology Holding Limited is a Chinese company focused on developing, manufacturing, and selling veterinary vaccines for livestock. They offer vaccines for a variety of animals and export to several countries.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Zhengye Biotechnology Holding (ZYBT)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — stalling growth underneath; a move to treat with suspicion, not chase. Business Quality: Thin; Financial Safety: Okay; Valuation: Fair; Growth Durability: Shrinking; Momentum: Rising.
- quarterly revenue $8M (Q4 FY2025, quarter ended Dec 2025)
- ROE -26.8% · ROA -16.3% · current ratio 1.14 · earnings yield -17.8% · free-cash-flow yield 9.8%
Holding back: weak fundamentals, soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 46 | Fair | |
| 46 | Fair | |
| 46 | Fair | |
| 46 | Fair | |
| 46 | Fair | |
| 46 | Fair |
The score was 46 in the stored Oct 3, 2026 snapshot and remains 46 in the current publication computed Oct 4, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $1.24 |
| Change on the day | -1.59% |
| 52-week range | $0.6155 – $14.30 |
| Market capitalisation | $58.8M |
| Shares traded on the day | 15.9K |
Price & events
Other perspectives
Council score for Zhengye Biotechnology Holding (ZYBT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ZYBT film — every key number, told as a short cinematic story
~2 min · open the film
What is Zhengye Biotechnology Holding (ZYBT), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Zhengye Biotechnology Holding Limited (ZYBT) is listed on NASDAQ. It employs 269 people and is led by Songlin Song. In Q4 FY2025 it reported revenue of $8M and net income of -$7M. The market values it at $58.8M.
What do the latest results show for Zhengye Biotechnology Holding (ZYBT)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $8M.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $8M | -$7M | -$0.15 (diluted) |
| Q3 FY2025 | $4M | -$4M | -$0.08 (diluted) |
What are the financial strengths and risks for Zhengye Biotechnology Holding (ZYBT)?
Short answer
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is weak fundamentals, soft growth. Trailing ratios: ROE -26.8% · ROA -16.3% · current ratio 1.14 · earnings yield -17.8% · free-cash-flow yield 9.8%.
How does Zhengye Biotechnology Holding compare with its peers?
Short answer
Zhengye Biotechnology Holding's score ranks tied for 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1.41 Oct 2, 2026 | $163M | 54 5-pillar Oct 4, 2026 | |
| Zhengye Biotechnology Holding (ZYBT) — this page | $1.24 | $58.8M | 46 |
| $9.34 Oct 2, 2026 | $119M | 46 5-pillar Oct 4, 2026 | |
| $3.21 Oct 2, 2026 | $38.4M | 44 5-pillar Oct 4, 2026 | |
| $1.33 Oct 2, 2026 | $171M | 36 5-pillar Oct 4, 2026 | |
| $0.95 Oct 2, 2026 | $134M | 35 5-pillar Oct 4, 2026 | |
| $7.39 Oct 2, 2026 | $111M | 34 5-pillar Oct 4, 2026 | |
| $5.42 Oct 2, 2026 | $64.2M | 31 5-pillar Oct 4, 2026 | |
| $3.44 Oct 2, 2026 | $22.0M | 29 5-pillar Oct 4, 2026 | |
| $2.05 Oct 2, 2026 | $23.7M | 25 5-pillar Oct 4, 2026 | |
| $8.65 Oct 2, 2026 | $34.9M | 24 5-pillar Oct 4, 2026 | |
| $0.66 Oct 2, 2026 | $26.6M | 24 5-pillar Oct 4, 2026 | |
| $2.07 Oct 2, 2026 | $22.2M | 24 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about Zhengye Biotechnology Holding (ZYBT)?
Zhengye Biotechnology Holding Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ZYBT research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ZYBT?
ZYBT carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Zhengye Biotechnology Holding Limited is a Chinese company focused on developing, manufacturing, and selling veterinary vaccines for livestock.
Is ZYBT a good stock to buy?
Stock Expert AI does not rate ZYBT buy, sell or hold. Zhengye Biotechnology Holding Limited carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ZYBT stock price today?
The last price recorded on this page for Zhengye Biotechnology Holding Limited (ZYBT) is $1.24, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ZYBT?
Zhengye Biotechnology Holding Limited faces several risks, including intense competition from established vaccine manufacturers, regulatory changes in China and export markets, and outbreaks of new animal diseases. Fluctuations in raw material costs and its negative profit margin also pose significant challenges. The company's small market capitalization and high beta further contribute to its risk profile.
What are the key factors to evaluate for ZYBT?
Zhengye Biotechnology Holding Limited (ZYBT) holds a MoonshotScore in the low range. The company's product portfolio includes vaccines for swine, cattle, goats, sheep, poultry, and dogs. Not financial advice.
How frequently does ZYBT data refresh on this page?
ZYBT's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ZYBT's recent stock price performance?
Zhengye Biotechnology Holding Limited (ZYBT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized in veterinary vaccines for livestock. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZYBT overvalued or undervalued right now?
Zhengye Biotechnology Holding Limited (ZYBT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ZYBT?
Fractional-share availability for Zhengye Biotechnology Holding Limited (ZYBT) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.24 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T09:24:52.960Z. | |
px.change | Change on the day | -1.59% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $58.8M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T09:24:52.243Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.02 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2025 | $8M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 15.9K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q4 FY2025 | -$7M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 2 quarters through Q4 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -26.8% · ROA -16.3% · current ratio 1.14 · earnings yield -17.8% · free-cash-flow yield 9.8% | — | UNRECORDED | Stored key metrics — Date unknown |
px.range52 | 52-week range | $0.6155 – $14.30 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 269 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Songlin Song | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 46 of 100 · Fair · pillars 26 / 45 / 63 / 1 / 74 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 46 (stored snapshot Oct 3, 2026) → 46 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.